This program is to develop therapeutic monoclonal antibody against the novel target – Siglec-15 (Sialic acid-binding immunoglobulin-type lectins 15). The highlight feature of this program is the use of the novel potential therapeutic target to treat cancer. We believe this program will be fairly unique and a leading program in current bio-pharmaceutical market.
Siglecs are cell surface receptors that can recognize sialylated glycans. And siglec-15 is a transmembrane protein consisting of 2 immunoglobulin-like domains, 1 transmembrane domain with a lysine residue, and a short cytoplasmic domain. It is usually expressed on dendritic cells or macrophages. Siglec-15 associates with DAP10 and DAP12 and acts as an activating signaling molecule on these proteins. Recently, scientists found that:
• Siglec-15 is a potential therapeutic target for cancer immunotherapy and plays an immune suppressor role.
• Siglec-15 is a candidate target for normalization cancer immunotherapy.
Fig.1 Siglec-15 is a candidate target for normalization cancer immunotherapy.1
Here are the published data about Siglec-15 that works as a potential target for normalization cancer immunotherapy.
• Siglec-15 is a critical immune suppressor.
• Siglec-15 is broadly upregulated on cancer cells and tumor-infiltrating myeloid cells.
• Siglec-15 inhibits T cell immune responses both in vitro and in vivo.
• Anti-Siglec-15 enhances anti-tumor immunity and suppresses tumor growth in mouse models.
Colon cancer, characterized by uncontrolled cell growth in the colon tissues, has been identified as one of the most common cancer in the world. It is sometimes referred to as colorectal cancer, a cancer which occurs on both colon and rectal areas. According to the published data, we can learn that Siglec-15 is highly expressed in colon cancer, compared with normal tissues. Other health indications for high expression of Siglec-15 include endometrioid cancer and thyroid cancer, etc.
• There are NO ongoing clinical trials that involve Siglec-15 target. Our program will be a pioneer in the field.
• As a novel potential target, Siglec-15 will be a shining star and owns a promising market prospect in the future. It has been reported that the expression of Siglec-15 is mutually exclusive to PD-L1. This may indicate that anti-Siglec-15 therapy can become supplement treatment for cancer patients with low PD-L1 expression.
With extensive experience in CRO services, we are confident in performing streamlined end-to-end program development. With our Next-IO™ programs, we are able to provide programs from antibody discovery, engineering, optimization, to pre-clinical studies. We will provide periodic progress to our partners to acheive timely communications.
Fig.2 The timeline of Next-IO™ programs.
Creative Biolabs is looking for potential partners to develop anti-Siglec-15 monoclonal antibody program. We can bring global strategic view into our trusted partnerships.
If you are interested in our programs (not limited to colon cancer, but also other indications you are interested), please feel free to contact us to learn more details about the cooperation activities.
For Research Use Only | Not For Clinical Use
Download our brochure